{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema:rydapt:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema%3Arydapt%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.005472,
    "timestamp_received": "2026-09-25T06:01:29.020697+00:00Z",
    "timestamp_returned": "2026-09-25T06:01:29.026169+00:00Z",
    "trace_id": "199d6cf1-8491-46ed-b584-e346a7edda3d"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "ind:ema:rydapt:0",
      "type": "Indication",
      "description": "Rydapt is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2017-09-18:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2017-09-18",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:rydapt",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Rydapt (midostaurin) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Novartis Europharm Ltd. Rydapt (midostaurin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Novartis Europharm Ltd.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Rydapt",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "midostaurin",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2017-10-25",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-07-26",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        }
      ]
    }
  ]
}